Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 453

1.

Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.

Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.

Am J Kidney Dis. 2005 Sep;46(3):481-8.

PMID:
16129210
2.

Current management of anemia in adult hemodialysis patients with end-stage renal disease.

Frankenfield DL, Johnson CA.

Am J Health Syst Pharm. 2002 Mar 1;59(5):429-35.

PMID:
11887409
3.

Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.

Oncologist. 2004;9(1):90-6. Erratum in: Oncologist. 2004;9(2):240.

4.

Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK.

Am J Kidney Dis. 2004 Jul;44(1):94-111.

PMID:
15211443
5.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group..

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642
6.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

Cancer. 2002 Aug 15;95(4):888-95.

7.

Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.

Hudis CA, Vogel CL, Gralow JR, Williams D; Procrit Study Group..

Clin Breast Cancer. 2005 Jun;6(2):132-42.

PMID:
16001991
8.

Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.

Voravud N, Sriuranpong V, Suwanrusme H.

J Med Assoc Thai. 2007 Jun;90(6):1082-8.

PMID:
17624200
9.

A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study.

Bren A, Kandus A, Varl J, Buturović J, Ponikvar R, Kveder R, Primozic S, Ivanovich P.

Artif Organs. 2002 Feb;26(2):91-7.

PMID:
11879235
10.

Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.

Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG.

Am J Kidney Dis. 2009 Sep;54(3):498-510. doi: 10.1053/j.ajkd.2009.05.007.

PMID:
19628315
12.

Perihospitalization hemoglobin-epoetin associations in U.S. hemodialysis patients, 1998 to 2003.

Solid CA, Foley RN, Gilbertson DT, Collins AJ.

Hemodial Int. 2007 Oct;11(4):442-7.

PMID:
17922742
13.

Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis.

Bárány P, Clyne N, Hylander B, Johansson AC, Simonsen O, Larsson R, Frisenette-Fich C, Svensson B, Helmers C.

Perit Dial Int. 1995;15(1):54-60.

PMID:
7734561
14.

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

Chang J, Couture F, Young S, McWatters KL, Lau CY.

J Clin Oncol. 2005 Apr 20;23(12):2597-605. Erratum in: J Clin Oncol. 2005 Aug 1;23(22):5276.

PMID:
15452188
15.

Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.

McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr; End-Stage Renal Disease Core Indicators Work Group..

Am J Kidney Dis. 2001 May;37(5):E36.

PMID:
11325701
16.

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.

Campos SM, Duh MS, Lefebvre P, Rosberg J.

J Natl Compr Canc Netw. 2005 Nov;3(6):807-16.

PMID:
16316616
17.

Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.

Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A.

Adv Ther. 2008 Nov;25(11):1215-28. doi: 10.1007/s12325-008-0111-1.

PMID:
18931828
18.

Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.

Bajetta E, Vercammen E, Reinhardt U, Janmohamed R, da Costa RM, Matulonis U, Guastalla JP; Epoetin Alfa Study Group..

Tumori. 2004 Sep-Oct;90(5):449-57.

PMID:
15656327
19.

Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.

Locatelli F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, Naso A, Rossi E, Formica M, Lombardi L, Rotolo U, Conte F.

J Nephrol. 2008 May-Jun;21(3):412-20.

PMID:
18587731
20.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators..

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46.

Supplemental Content

Support Center